PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed on Prior Endocrine
Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival - ScienceDirect
Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2− advanced breast cancer (PALOMA-1, TRIO-18) | SpringerLink
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | NEJM
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer | NEJM
Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients | SpringerLink
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
.jpg "Treating metastatic breast cancer: Analysis of the Paloma-3 Trial")
Treating metastatic breast cancer: Analysis of the Paloma-3 Trial
Table 1 from PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That Progressed
Overall Survival with Palbociclib and Fulvestrant in Advanced Breast Cancer | Semantic Scholar
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
IJMS | Free Full-Text | Progression-Free Survival and Overall Survival of CDK 4/6 Inhibitors Plus Endocrine Therapy in Metastatic Breast Cancer: A Systematic Review and Meta-Analysis
ESMO | Press Release | PALOMA3 palbociclib fulvestrant
PALOMA-3: Overall survival (OS) with palbociclib plus fulvestrant in HR+,HER2_ ABC - YouTube
Palbociclib verlängert Gesamtüberleben nicht signifikant - 01 - 2019 - Heftarchiv - AMT
Kaplan-Meier curves of progression-free survival among patients in... | Download Scientific Diagram
Final analysis of progression-free survival in the PALOMA-3 study... | Download Scientific Diagram
Palbociclib plus endocrine therapy in older women with HR+/HER2– advanced breast cancer: a pooled analysis of randomised PALOMA clinical studies - ScienceDirect
Comparative effectiveness of first line palbociclib plus letrozole vs. letrozole alone for hormone-receptor positive metastatic breast cancer in real world clinical practice - BJMO
Comparative biomarker analysis of PALOMA-2/3 trials for palbociclib | npj Precision Oncology
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor‐positive/human epidermal growth factor receptor 2‐negative metastatic breast cancer - Gelmon - 2020 - The Breast Journal -
![ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR](https://cdn.koreabiomed.com/news/photo/202206/13831_14395_1052.jpg "ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR")
ASCO 2022] Ibrance fails to improve survival in 1st-line breast cancer treatment < Pharma < Article - KBR
Real-World Effectiveness of Palbociclib Versus Clinical Trial Results in Patients With Advanced/Metastatic Breast Cancer That Progressed on Previous Endocrine Therapy - Tam Binh V Bui, Desirée MT Burgers, Mariette J Agterof, Ewoudt
PALOMA-3: PFS by Subtype Distribution. a Intrinsic subtype distribution... | Download Scientific Diagram
